Overview

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Bristol-Myers Squibb
Treatments:
Metformin
Saxagliptin